Drug updated on 3/28/2024
| Dosage Form | Injection (subcutaneous; 0.6 mg/0.6 mL) |
| Drug Class | Antihypoglycemic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Summary
- Dasiglucagon (Zegalogue) is a glucagon analog used for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
- According to two systematic reviews/meta-analyses, dasiglucagon has been found effective at reducing recovery time from hypoglycemia or increasing blood glucose levels by 20 mg/dL from baseline compared to both native glucagon and placebo.
- The safety outcomes of dasiglucagon were comparable with those of native glucagon, indicating that it can be considered as a safe alternative for treating severe hypoglycemia in type 1 diabetes mellitus (T1DM) patients.
- In one study involving T1DM patients experiencing insulin-induced hypoglycemia, dasiglucagon was shown to be more effective than oral glucose or placebo but not superior to conventional glucagon.
- These findings are based on data extracted from five randomized controlled trials included in the meta-analysis studies reviewed; however, no specific population subgroups were mentioned within these documents regarding differential effects or considerations related to age, sex or ethnicity among others.
- Despite its demonstrated efficacy and safety profile according to these systematic reviews/meta-analyses comprising five clinical trials overall, further research may still be needed given that there was no statistically significant difference between dasiglucagon's performance versus conventional glucagons' when managing insulin-induced hypoglycaemic episodes in T1DM patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zegalogue (dasiglucagon) Prescribing Information. | 2023 | Rechon Life Science AB Malmö, Sweden |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis. | 2023 | Expert Review of Clinical Pharmacology |
| Dasiglucagon for the treatment of insulin-induced hypoglycemia in patients with type 1 diabetes mellitus: a meta-analysis. | 2023 | Balkan Medical Journal |